Diagnostic Criteria in Cardiac Sarcoidosis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Heart Center Leipzig - University Hospital
- Trial code
- NCT04737317
- Record updated
- 9 May 2023
- Original description
The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.Read full original descriptionShow less
Evaluation of Diagnostic Criteria in Cardiac Sarcoidosis - an Observational Study
The purpose of the study is to evaluate the accuracy of the current diagnostic criteria of cardiac sarcoidosis.
Inclusion: patients with suspected CS due to the following presentations:; age < 65 years and new higher degree AV block, causative coronary artery disease excluded; age < 65 years and new ventricular tachycardia, causative coronary artery disease excluded; age < 65 years and ventricular tachycardia, causative coronary artery disease excluded; extracardiac sarcoidosis and cardiac involvement suggested (palpitations, abnormal ECG, abnormal echocardiography); To diagnose CS one of the following diagnostic tools will be used:; World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG); Heart Rhythm Society expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis; Japanese Society of Nuclear Cardiology (JSNC); Patients whit histological confirmation from myocardial tissue fullfil will be defined as proven CS. (Group 1); Patients with clinical and imaging findings highly suggesting CS, but without histological confirmation from myocardial biopsy will be defined as probable CS (Group 2); Patients who do not fullfil the criteria or exhibiting findings suggesting an alternative, more likely diagnosis, will be considered as unlikely CS (Group 3).
Exclusion: noncompliant patients refusing the recommended therapy; age < 18 years; unable or unwilling to provide informed consent; patients who are pregnant or lactating.